A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.
Fawcett leads a team of communicators who produce targeted, innovative communication for the Rogel Cancer Center’s research and clinical enterprises. Prior to Michigan Medicine, Fawcett was a reporter at the Detroit News and editor for a web-based community for people with disabilities.
HPV circulating tumor DNA and MRI/PET imaging markers predicted which tumors would respond to chemoradiation as early as two weeks into treatment.
Bolstering a specific enzyme within the mitochondria of intestinal cells helped mitigate GI disease induced by T cells after bone marrow transplant, cancer immunotherapy.
A new perspective looks at the built-in bias within the factors that drive physicians’ salaries and makes recommendations for how institutions can close the gap.
In a clinical trial, adding interferon treatment with a bone marrow transplant bolstered outcomes for patients with advanced, high-risk leukemia.
A protein called PIKfyve impacts multiple processes involved in metabolism and cell death; blocking it is key to making immunotherapy work in prostate cancer.